Home » Authors » Brady Huggett

Articles by Brady Huggett

Cypress Bioscience Raises $10.3M For Milnacipran Phase III Program

March 28, 2003

By Brady Huggett

Cypress Bioscience Raises $10.3M For Milnacipran Phase III Program

March 28, 2003

By Brady Huggett

Alteon Raises $7.7M Privately For ALT-711, Other Products

March 27, 2003

By Brady Huggett

Merck Accepts Kalypsys Invite, Ends Up Signing Platform Deal

March 27, 2003

By Brady Huggett

Merck Accepts Kalypsys Invite, Ends Up Signing Platform Deal

March 27, 2003

By Brady Huggett

Alteon Raises $7.7M Privately For ALT-711, Other Products

March 27, 2003

By Brady Huggett

Biopure Plans To Raise $13.4M While Awaiting Word From FDA

March 26, 2003

By Brady Huggett

Biopure Plans To Raise $13.4M While Awaiting Word From FDA

March 26, 2003

By Brady Huggett

Dermatology Meeting Brings Together Psoriasis Competitors

March 25, 2003

By Brady Huggett

Dermatology Meeting Brings Together Psoriasis Competitors

March 25, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...